Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial-Reference-Cited by-同舟云学术

Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial

Published:2018-01 Issue:1 Volume:19 Page:87-100
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Di Leo Angelo,Johnston Stephen,Lee Keun Seok,Ciruelos Eva,Lønning Per E,Janni Wolfgang,O'Regan Ruth,Mouret-Reynier Marie-Ange,Kalev Dimitar,Egle Daniel,Csőszi Tibor,Bordonaro Roberto,Decker Thomas,Tjan-Heijnen Vivianne C G,Blau Sibel,Schirone Alessio,Weber Denis,El-Hashimy Mona,Dharan Bharani,Sellami Dalila,Bachelot Thomas

Publisher

Elsevier BV

Subject

Oncology

Reference37 articles.

1. A 2009 update on the treatment of patients with hormone receptor-positive breast cancer;Cleator;Clin Breast Cancer,2009

2. Estrogen receptor pathway: resistance to endocrine therapy and new therapeutic approaches;Moy;Clin Cancer Res,2006

3. Biological determinants of endocrine resistance in breast cancer;Musgrove;Nat Rev Cancer,2009

4. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer;Miller;J Clin Invest,2010

5. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer;Baselga;N Engl J Med,2012

Cited by 318 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the role of PIK3R1 in cancer: A comprehensive review of regulatory signaling and therapeutic implications;Seminars in Cancer Biology;2024-11

2. Efficacy and Safety of Phosphatidylinositol 3-kinase Inhibitors for Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials;Current Cancer Drug Targets;2024-09

3. Significance of phosphoinositide 3-kinase inhibitors in advanced breast cancer: a systematic review and meta-analysis;Clinical and Translational Oncology;2024-08-10

4. Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyond;Critical Reviews in Oncology/Hematology;2024-08

5. Role of molecular biology in the management of pancreatic cancer;World Journal of Gastrointestinal Oncology;2024-07-15